These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 18984874)

  • 21. Statistical considerations for the design and analysis of Phase III clinical trials in prostate cancer.
    Halabi S
    Urol Oncol; 2008; 26(3):300-7. PubMed ID: 18452825
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Improving the efficiency of estimation in randomized trials of adaptive treatment strategies.
    Lavori PW; Dawson R
    Clin Trials; 2007; 4(4):297-308. PubMed ID: 17848491
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Statistical and clinical significance: alternative methods for understanding the importance of research findings.
    Glaros AG
    J Ir Dent Assoc; 2004; 50(3):128-31. PubMed ID: 15481525
    [TBL] [Abstract][Full Text] [Related]  

  • 24. On the evolution of statistical methods as applied to clinical trials.
    Machin D
    J Intern Med; 2004 May; 255(5):521-8. PubMed ID: 15078495
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The emperor's new clothes or the current practice of clinical trials for multiple myeloma in the USA.
    Ballester O
    Cancer Invest; 2008 Jun; 26(5):445-7. PubMed ID: 18568765
    [TBL] [Abstract][Full Text] [Related]  

  • 26. An examination of the efficiency of the sequential parallel design in psychiatric clinical trials.
    Tamura RN; Huang X
    Clin Trials; 2007; 4(4):309-17. PubMed ID: 17848492
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Re: "use of a Bayesian approach to decide when to stop a therapeutic trial: the case of a chemoprophylaxis trial in human immunodeficiency virus infection".
    van Noord PA; van der Tweel I
    Am J Epidemiol; 2005 Nov; 162(10):1033-5. PubMed ID: 16221807
    [No Abstract]   [Full Text] [Related]  

  • 28. Flexible design of two-stage adaptive procedures for phase III clinical trials.
    Koyama T
    Contemp Clin Trials; 2007 Jul; 28(4):500-13. PubMed ID: 17307399
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Clinical trials: principles of the method].
    Aboulker JP
    Rev Prat; 2000 Apr; 50(8):829-32. PubMed ID: 10874858
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The clinical significance of new therapies for the management of periodontal disease.
    Van Dyke TE
    J Int Acad Periodontol; 2005 Oct; 7(4 Suppl):191-6. PubMed ID: 16248275
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Analysis and importance of statistical power and sample size in empirical scientific research].
    Klimek KM
    Wiad Lek; 2008; 61(7-9):211-5. PubMed ID: 19172834
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Standard versus adaptive monitoring procedures: A commentary.
    Fleming TR
    Stat Med; 2006 Oct; 25(19):3305-12; discussion 3313-4, 3326-47. PubMed ID: 16850447
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Statistical methods in the evaluation of the therapeutic efficacy--their problems and solutions].
    Tominaga S
    Gan To Kagaku Ryoho; 1982 Nov; 9(11):1873-81. PubMed ID: 6764094
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A hybrid Bayesian-frequentist approach to evaluate clinical trial designs for tests of superiority and non-inferiority.
    Shao Y; Mukhi V; Goldberg JD
    Stat Med; 2008 Feb; 27(4):504-19. PubMed ID: 17854052
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Bayesian decision sequential analysis with survival endpoint in phase II clinical trials.
    Zhao L; Woodworth G
    Stat Med; 2009 Apr; 28(9):1339-52. PubMed ID: 19226557
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Statistical significance, power and sample size--Part 2.
    Christley RM
    J Small Anim Pract; 2008 Jul; 49(7):321-2. PubMed ID: 18638056
    [No Abstract]   [Full Text] [Related]  

  • 37. Clinical trials with allergen products--statistical considerations.
    Volkers P
    Arb Paul Ehrlich Inst Bundesamt Sera Impfstoffe Frankf A M; 2006; (95):172-80; discussion 181. PubMed ID: 17393737
    [No Abstract]   [Full Text] [Related]  

  • 38. Statistical methods in clinical trials.
    Gebski VJ; Keech AC
    Med J Aust; 2003 Feb; 178(4):182-4. PubMed ID: 12580749
    [No Abstract]   [Full Text] [Related]  

  • 39. Re: Design and endpoints of clinical trials in hepatocellular carcinoma.
    Di Maio M; Daniele B; Gallo C; Perrone F
    J Natl Cancer Inst; 2008 Nov; 100(21):1557; author reply 1557-8. PubMed ID: 18957679
    [No Abstract]   [Full Text] [Related]  

  • 40. Adaptive designs for confirmatory clinical trials.
    Bretz F; Koenig F; Brannath W; Glimm E; Posch M
    Stat Med; 2009 Apr; 28(8):1181-217. PubMed ID: 19206095
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.